April 20, 2024
Market Now
Samsung Bioepis remains in red in 2018 with W102.8b operating loss
[DISCLOSURE] Samsung BioLogics (207940) reported on Feb. 13 that its subsidiary Samsung Bioepis’ operating loss in 2018 has decreased 0.7 percent to 102.78 billion won (US$91.36 million) from the previous year.
Revenue increased 17.5 percent on-year to 369.78 billion won and net loss remained in the red coming in at 55.0 billion won.
By Hwang You-mee (glamazon@heraldcorp.com)
Revenue increased 17.5 percent on-year to 369.78 billion won and net loss remained in the red coming in at 55.0 billion won.
By Hwang You-mee (glamazon@heraldcorp.com)
